Gene

RAD51

RAD51 recombinase

Explore in graph →CI-GENE-00022860HGNC:9817 ENSG00000051180 NCBI 5888 Cancer geneApproved

Curated evidence

Clinical evidence (12)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–12 of 12 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
RAD51 e24::e42
Afatinib	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID12369 A 62 year-old female never smoker diagnosed of lung adenocarcinoma that was negative for EGFR and ALK alterations (EGFR hotspot tissue NGS) was treated with carboplatin/ pemetrexed/ bevacizumab (x 6 c… (full text at CIViC) PMID 29472054 · Raez et al., 2018 · Open in CIViC	civic
Erlotinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	4	accepted	EID12360 A 48 year old male with lung adenocarcinoma who was a smoker presented with diminished vision and tinnitus, and multiple intracranial brain metastasis were identified by CT. Metastatic site was submit… (full text at CIViC) PMID 29290255 · Zhu et al., 2018 ·

Cohorts

Alteration frequency by cohort (6)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved6 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Comparison of Cutaneous Sarcomas, CSCC and Deeper Sarcomas (DFCI, 2026) sarcoma_dfci_genie_2026	unmapped	Ssm	4	48	8.3%	134

Literature

Linked publications (7)

25 per page, newest first.

pubmedPublishedShowing 1–7 of 7 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.
· Cancer Discov · 2016 · PMID 27102076 · validated civic_curation pubmed
EGFR-RAD51 fusion variant in lung adenocarcinoma and response to erlotinib: A case report.
· Lung Cancer · 2018 · PMID 29290255 · validated civic_curation pubmed
EGFR-RAD51 fusion in lung adenocarcinoma with systemic and intracranial response to osimertinib: A case report and review of the literature.
· Lung Cancer · 2022 · PMID 35245845 · validated civic_curation pubmed
EGFR-RAD51 Fusion: A Targetable Partnership Originated from the Tumor Evolution?
· J Thorac Oncol · 2018 · PMID 29472054 · validated civic_curation pubmed

RAD51 Fusion10
(functional)	—UNRESOLVED	Functional	D	Supports Gain Of Function	4	submitted	EID11016 Expression of EGFR::RAD51 via retroviral transfection in IL-3 dependent murine Ba/F3 cells results in activation of Pi3K/AKT pathway (Fig. 2C, increased levels of pAKT), and IL-3 independent prolifera… (full text at CIViC) PMID 27102076 · Konduri et al., 2016 · Open in CIViC	civic
Afatinib	Lung Adenocarcinoma	Predictive	D	Supports Sensitivity Response	3	submitted	EID11019 Response to Afatinib was assessed by measuring viability of Ba/F3 cells expressing the EGFR::RAD51 variant 72 hours after treatment with Afatinib (10-1000 nmol/L). Viability was measured using the Cel… (full text at CIViC) PMID 27102076 · Konduri et al., 2016 · Open in CIViC	civic
Erlotinib	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	4	accepted	EID11015 The paper reports three patients (P1, P2 and P4) with Stage IV lung adenocarcinoma with metastasis, harboring the EGFR::RAD51 fusion detected by hybrid capture NGS (FoundationOne). Breakpoints were in… (full text at CIViC) PMID 27102076 · Konduri et al., 2016 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID5909 A 48-year-old Chinese man with right lung tumor and multiple brain metastases of a lung adenocarcinoma (T1N2M1, stage IV). NGS analysis indicated an EGFR-RAD51 fusion rather than the most common kind… (full text at CIViC) PMID 29290255 · Zhu et al., 2018 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	D	Supports Sensitivity Response	3	submitted	EID11017 Response to Erlotinib was assessed by measuring viability of Ba/F3 cells expressing the EGFR::RAD51 variant 72 hours after treatment with Erlotinib (10-1000 nmol/L). Viabilty was measured using the Ce… (full text at CIViC) PMID 27102076 · Konduri et al., 2016 · Open in CIViC	civic
Erlotinib + OsimertinibSequential	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID12370 This is a case report of 29-year-old diagnosed with metastatic adenocarcinoma of the left lung. The patient was treated with chemotherapy (cisplatin 75 mg/m2 and pemetrexed 500 mg/m2 every 3 weeks) an… (full text at CIViC) PMID 35399574 · Di Federico et al., 2022 · Open in CIViC	civic
Gefitinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	3	accepted	EID12371 A 37-year-old never smoker was diagnosed of pulmonary adenocarcinoma with mucinous pattern. FoundationOne DX1 panel detected an EGFR::RAD51 fusion and the patient was treated with first-line gefitinib… (full text at CIViC) PMID 35399574 · Di Federico et al., 2022 · Open in CIViC	civic
Icotinib	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID7314 A 26 year old non-smoker was diagnosed with lung adenocarcinoma and underwent thoracoscopic resection and treatment with cisplatin and pemetrexed. Panel NGS sequencing of the surgical sample detected … (full text at CIViC) PMID 31064887 · Guan et al., 2019 · Open in CIViC	civic
Osimertinib	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID11021 Case report of a 30-year-old male with lung adenocarcinoma and metastasis to several organs, including several lesions in the brain. NGS assay (Foundation One CDX panel) detected the EGRF::RAD51 fusio… (full text at CIViC) PMID 35245845 · Copia Sperandio et al., 2022 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID12372 This is a case report of a 45-year-old male never smoker that was diagnosed with metastatic lung adenocarcinoma. The patient responded poorly to the initial chemoimmunotherapy (carboplatin, pemetrexed… (full text at CIViC) PMID 38525318 · Lai et al., 2024 · Open in CIViC	civic

RAD51 Fusion10

(functional)

—UNRESOLVED

Functional

Supports Gain Of Function

submitted

EID11016

Expression of EGFR::RAD51 via retroviral transfection in IL-3 dependent murine Ba/F3 cells results in activation of Pi3K/AKT pathway (Fig. 2C, increased levels of pAKT), and IL-3 independent prolifera… (full text at CIViC)

PMID 27102076 · Konduri et al., 2016 · Open in CIViC

civic

Afatinib

Lung Adenocarcinoma

Predictive

Supports Sensitivity Response

submitted

EID11019

Response to Afatinib was assessed by measuring viability of Ba/F3 cells expressing the EGFR::RAD51 variant 72 hours after treatment with Afatinib (10-1000 nmol/L). Viability was measured using the Cel… (full text at CIViC)

PMID 27102076 · Konduri et al., 2016 · Open in CIViC

civic

Erlotinib

Lung Adenocarcinoma

Predictive

Supports Sensitivity Response

accepted

EID11015

The paper reports three patients (P1, P2 and P4) with Stage IV lung adenocarcinoma with metastasis, harboring the EGFR::RAD51 fusion detected by hybrid capture NGS (FoundationOne). Breakpoints were in… (full text at CIViC)

PMID 27102076 · Konduri et al., 2016 · Open in CIViC

civic

〃

Lung Adenocarcinoma

Predictive

Supports Sensitivity Response

accepted

EID5909

A 48-year-old Chinese man with right lung tumor and multiple brain metastases of a lung adenocarcinoma (T1N2M1, stage IV). NGS analysis indicated an EGFR-RAD51 fusion rather than the most common kind… (full text at CIViC)

PMID 29290255 · Zhu et al., 2018 · Open in CIViC

civic

〃

Lung Adenocarcinoma

Predictive

Supports Sensitivity Response

submitted

EID11017

Response to Erlotinib was assessed by measuring viability of Ba/F3 cells expressing the EGFR::RAD51 variant 72 hours after treatment with Erlotinib (10-1000 nmol/L). Viabilty was measured using the Ce… (full text at CIViC)

PMID 27102076 · Konduri et al., 2016 · Open in CIViC

civic

Erlotinib + OsimertinibSequential

Lung Adenocarcinoma

Predictive

Supports Sensitivity Response

accepted

EID12370

This is a case report of 29-year-old diagnosed with metastatic adenocarcinoma of the left lung. The patient was treated with chemotherapy (cisplatin 75 mg/m2 and pemetrexed 500 mg/m2 every 3 weeks) an… (full text at CIViC)

PMID 35399574 · Di Federico et al., 2022 · Open in CIViC

civic

Gefitinib

Lung Non-Small Cell CarcinomaCURATED_BROADER

Predictive

Supports Sensitivity Response

accepted

EID12371

A 37-year-old never smoker was diagnosed of pulmonary adenocarcinoma with mucinous pattern. FoundationOne DX1 panel detected an EGFR::RAD51 fusion and the patient was treated with first-line gefitinib… (full text at CIViC)

PMID 35399574 · Di Federico et al., 2022 · Open in CIViC

civic

Icotinib

Lung Adenocarcinoma

Predictive

Supports Sensitivity Response

accepted

EID7314

A 26 year old non-smoker was diagnosed with lung adenocarcinoma and underwent thoracoscopic resection and treatment with cisplatin and pemetrexed. Panel NGS sequencing of the surgical sample detected … (full text at CIViC)

PMID 31064887 · Guan et al., 2019 · Open in CIViC

civic

Osimertinib

Lung Adenocarcinoma

Predictive

Supports Sensitivity Response

accepted

EID11021

Case report of a 30-year-old male with lung adenocarcinoma and metastasis to several organs, including several lesions in the brain. NGS assay (Foundation One CDX panel) detected the EGRF::RAD51 fusio… (full text at CIViC)

PMID 35245845 · Copia Sperandio et al., 2022 · Open in CIViC

civic

〃

Lung Adenocarcinoma

Predictive

Supports Sensitivity Response

accepted

EID12372

This is a case report of a 45-year-old male never smoker that was diagnosed with metastatic lung adenocarcinoma. The patient responded poorly to the initial chemoimmunotherapy (carboplatin, pemetrexed… (full text at CIViC)

PMID 38525318 · Lai et al., 2024 · Open in CIViC

civic